The chemical class known as C20ORF29 Inhibitors comprises a diverse array of compounds that are capable of influencing the function of the C20ORF29 protein by targeting various cellular pathways and processes integral to vesicular transport and endosomal-lysosomal trafficking. While these inhibitors do not engage directly with C20ORF29, their mode of action entails modifying the cellular environment or the functionality of other proteins and processes crucial for C20ORF29's operation. This strategy stems from the recognition that C20ORF29's activity and efficiency are intricately linked to a complex network of intracellular pathways, especially those involved in vesicle formation, transport, and the sorting of transmembrane proteins to lysosomes and endosomes.
In this class, some compounds are known to disrupt lysosomal acidification, a vital process for protein sorting in these organelles, which could possibly inhibit C20ORF29. Others may interfere with endocytic pathways by altering endosomal pH, impacting endosomal sorting and trafficking processes that could possibly inhibit C20ORF29. Moreover, the class includes compounds that target cytoskeletal components and dynamics crucial for vesicle movement within cells. By disrupting actin filaments or microtubules, these inhibitors impede vesicular transport, which could possibly inhibit the role of C20ORF29 in this process. Additionally, some inhibitors focus on altering functions of the Golgi apparatus, another key player in vesicular transport, thus influencing the overall process involving C20ORF29. Overall, the action of C20ORF29 Inhibitors is marked by their potential to modulate various cellular processes that are connected to the functionality of C20ORF29. By targeting these pathways, these compounds could possibly inhibit C20ORF29 by altering the conditions necessary for its optimal performance, leading to changes in its activity within the cell. This approach underlines the complexity and interconnectivity of cellular pathways and underscores the potential of influencing specific proteins by targeting related processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Could possibly inhibit C20orf29 by affecting endosomal acidification, impacting its role in endosomal-lysosomal transport. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Could possibly inhibit C20orf29 by disrupting endosomal transport, influencing its role in endosomal-lysosomal pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Could possibly inhibit C20orf29 in vesicular trafficking pathways as a PI3K inhibitor. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Could possibly inhibit C20orf29 by impacting endocytic trafficking relevant to its function through dynamin inhibition. | ||||||
YM201636 | 371942-69-7 | sc-204193 | 5 mg | $217.00 | 6 | |
Could possibly inhibit C20orf29 by influencing endosomal sorting and trafficking as a PIKfyve inhibitor. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Could possibly inhibit C20orf29 by affecting vesicular transport pathways through microtubule dynamics disruption. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Could possibly inhibit C20orf29 by impacting transport processes associated with microtubule depolymerization. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Could possibly inhibit C20orf29 in actin-dependent trafficking processes by inhibiting actin polymerization. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Could possibly inhibit C20orf29 in trafficking processes as a tyrosine kinase inhibitor. | ||||||
FCM Lysing solution (1x) | sc-3621 | 150 ml | $62.00 | 8 | ||
Could possibly inhibit C20orf29 by raising lysosomal pH, affecting its role in lysosomal trafficking. | ||||||